Aeon Biopharma, INC. (AEON) — SEC Filings

Q: What are the key financial highlights for Aeon Biopharma, INC.?

Key financial highlights for Aeon Biopharma, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Aeon Biopharma, INC.?

Key executives at Aeon Biopharma, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Aeon Biopharma, INC. stock?

Risk factors for Aeon Biopharma, INC. (AEON) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Aeon Biopharma, INC.?

Forward-looking statements and predictions from Aeon Biopharma, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Aeon Biopharma, INC.. Recent DEF 14A filing on Dec 29, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Aeon Biopharma, INC. on SEC EDGAR

Overview

Aeon Biopharma, INC. (AEON) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEF 14A filed on Dec 29, 2025: AEON Biopharma, Inc. is holding a Special Meeting on January 21, 2026, to approve critical financing and equity proposals aimed at funding the development and potential commercialization of ABP-450, a biosimilar to BOTOX. The company seeks stockholder approval for a PIPE Financing Proposal, which in

Sentiment Summary

Across 49 filings, the sentiment breakdown is: 6 bearish, 41 neutral, 2 mixed. The dominant filing sentiment for Aeon Biopharma, INC. is neutral.

Filing Type Overview

Aeon Biopharma, INC. (AEON) has filed 4 DEF 14A, 29 8-K, 5 10-Q, 3 10-K/A, 2 10-K, 2 SC 13G, 3 S-1/A, 1 SC 13G/A with the SEC between Feb 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (49)

AEON Biopharma Seeks Shareholder Nod for Critical Financing, Equity Deals — DEF 14A · Dec 29, 2025 Risk: high
AEON Biopharma, Inc. is holding a Special Meeting on January 21, 2026, to approve critical financing and equity proposals aimed at funding the development and p
AEON Biopharma Files 8-K: Agreements, Equity Sales — 8-K · Dec 15, 2025 Risk: medium
AEON Biopharma, Inc. filed an 8-K on December 15, 2025, reporting on several key events. These include entering into a material definitive agreement, unregister
AEON Biopharma Files 8-K: Reg FD & Financials — 8-K · Dec 4, 2025 Risk: low
AEON Biopharma, Inc. filed an 8-K on December 4, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly know
AEON Biopharma Narrows Loss, Pivots to Biosimilar Strategy — 10-Q · Nov 14, 2025 Risk: high
AEON Biopharma, Inc. reported a net loss of $2.085 million for the nine months ended September 30, 2025, a significant improvement from the net income of $39.92
AEON Biopharma Files 8-K on Agreements and Equity Sales — 8-K · Nov 13, 2025 Risk: medium
AEON Biopharma, Inc. filed an 8-K on November 12, 2025, reporting on entering a material definitive agreement, unregistered sales of equity securities, and fina
AEON Biopharma Files 8-K — 8-K · Sep 8, 2025 Risk: low
AEON Biopharma, Inc. filed an 8-K on September 8, 2025, reporting on Regulation FD disclosures and financial statements. The company, formerly known as Priveter
AEON Shifts Strategy to Biosimilar, Reports Q2 Loss Amid Cash Infusion — 10-Q · Aug 12, 2025 Risk: high
AEON Biopharma, Inc. reported a net income of $2.453 million for the six months ended June 30, 2025, a significant decrease from $46.094 million in the same per
AEON Biopharma Files 8-K on Shareholder Vote Matters — 8-K · Jun 13, 2025 Risk: low
AEON Biopharma, Inc. filed an 8-K on June 13, 2025, to report on matters submitted to a vote of its security holders. The filing details the submission of speci
AEON Biopharma Amends 2024 10-K, Maintains Emerging Growth Status — 10-K/A · Jun 11, 2025 Risk: medium
AEON Biopharma, Inc. filed a 10-K/A on June 11, 2025, for the fiscal year ended December 31, 2024, primarily to amend its annual report. As a clinical-stage bio
AEON Biopharma Files 8-K with Financials — 8-K · May 20, 2025 Risk: low
AEON Biopharma, Inc. filed an 8-K on May 20, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly known as
AEON Biopharma Files 10-Q for Q1 2025 — 10-Q · May 14, 2025 Risk: medium
AEON Biopharma, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Priveterra Acquisition Corp., is in the pharmaceutical
AEON Biopharma Files 2024 Proxy Statement — DEF 14A · Apr 29, 2025 Risk: low
AEON Biopharma, Inc. filed its definitive proxy statement for the fiscal year ending December 31, 2024. The filing, dated April 29, 2025, outlines the company's
AEON Biopharma Faces Delisting Concerns — 8-K · Apr 25, 2025 Risk: high
AEON Biopharma, Inc. filed an 8-K on April 25, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company, fo
AEON Biopharma Announces Director & Officer Changes — 8-K · Apr 21, 2025 Risk: medium
AEON Biopharma, Inc. announced on April 19, 2025, changes related to its board of directors and executive compensation. The filing details the departure of cert
AEON Biopharma Announces Board and Officer Changes — 8-K · Apr 8, 2025 Risk: medium
AEON Biopharma, Inc. announced on April 3, 2025, a change in its board of directors. Specifically, the company reported the departure of certain directors and t
AEON Biopharma Files 8-K on Director Changes & Compensation — 8-K · Mar 27, 2025 Risk: low
AEON Biopharma, Inc. filed an 8-K on March 27, 2025, reporting on the departure of directors or certain officers, the election of directors, and compensatory ar
AEON Biopharma Files 2024 10-K, Details Financials — 10-K · Mar 24, 2025 Risk: medium
AEON Biopharma, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, formerly known as Priveterra Acquisition Corp., reported various
AEON Biopharma Files 8-K for Reg FD and Financials — 8-K · Mar 10, 2025 Risk: low
AEON Biopharma, Inc. filed an 8-K on March 10, 2025, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known
AEON Biopharma Files 8-K on Corporate Actions — 8-K · Feb 24, 2025 Risk: low
AEON Biopharma, Inc. filed an 8-K on February 24, 2025, reporting on several items including material modifications to security holder rights, amendments to its
AEON Biopharma Faces Delisting Concerns — 8-K · Feb 7, 2025 Risk: high
AEON Biopharma, Inc. filed an 8-K on February 7, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company w
AEON Biopharma Files Definitive Proxy Statement — DEF 14A · Jan 23, 2025 Risk: low
AEON Biopharma, Inc. filed its definitive proxy statement on January 23, 2025, for its annual meeting on February 24, 2025. The company, formerly known as Prive
AEON Biopharma Files Current Report on Form 8-K — 8-K · Jan 7, 2025 Risk: low
On January 6, 2025, AEON Biopharma, Inc. entered into a material definitive agreement. The company, formerly known as Priveterra Acquisition Corp., is incorpora
AEON Biopharma Files 8-K — 8-K · Jan 6, 2025 Risk: low
AEON Biopharma, Inc. filed an 8-K on January 6, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known
AEON Biopharma Files 8-K for Amendments and Financials — 8-K · Dec 20, 2024 Risk: low
AEON Biopharma, Inc. filed an 8-K on December 18, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, f
SC 13G Filing — SC 13G · Nov 14, 2024
AEON Biopharma Q3 2024 10-Q Filed — 10-Q · Nov 13, 2024 Risk: medium
AEON Biopharma, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $37,159,600 and total liabilities of $39,587,
AEON Biopharma Files 8-K for Reg FD and Financials — 8-K · Oct 7, 2024 Risk: low
AEON Biopharma, Inc. filed an 8-K on October 7, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known
AEON Biopharma Files 2023 10-K Amendment — 10-K/A · Aug 12, 2024 Risk: low
AEON Biopharma, Inc. filed an amendment (Amendment No. 2) to its annual report on Form 10-K for the fiscal year ended December 31, 2023. The filing, dated Augus
AEON Biopharma Files 8-K on Operations — 8-K · Aug 12, 2024 Risk: low
AEON Biopharma, Inc. filed an 8-K on August 12, 2024, reporting on its results of operations and financial condition. The filing includes financial statements a
AEON Biopharma 10-Q: Assets Rise, Cohen Capital Markets Event — 10-Q · Aug 12, 2024 Risk: medium
AEON Biopharma, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $39,122,238 as of June 30, 2024, a slight increase
AEON Biopharma Files 8-K for Disclosure and Exhibits — 8-K · Aug 6, 2024 Risk: low
AEON Biopharma, Inc. filed an 8-K on August 6, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as
AEON Biopharma Files S-1/A Amendment — S-1/A · Jul 23, 2024 Risk: medium
AEON Biopharma, Inc. filed an S-1/A amendment on July 23, 2024, for its registration statement. The company, previously known as Priveterra Acquisition Corp. un
AEON Biopharma Files 8-K — 8-K · Jul 9, 2024 Risk: low
AEON Biopharma, Inc. filed an 8-K on July 9, 2024, to report other events. The company, formerly known as Priveterra Acquisition Corp. until December 22, 2020,
AEON Biopharma Files 8-K on Security Holder Vote Matters — 8-K · Jun 14, 2024 Risk: low
AEON Biopharma, Inc. filed an 8-K on June 14, 2024, to report on the submission of matters to a vote of its security holders. The company, formerly known as Pri
AEON Biopharma Files S-1/A for Share Registration — S-1/A · May 31, 2024 Risk: medium
AEON Biopharma, Inc. filed an S-1/A on May 31, 2024, to register 6,971,500 shares of common stock. The company, formerly Priveterra Acquisition Corp., is focuse
AEON Biopharma Appoints New CMO, Director — 8-K · May 16, 2024 Risk: medium
AEON Biopharma, Inc. announced on May 16, 2024, the appointment of Dr. Robert L. Ferris as Chief Medical Officer and the election of Ms. Sarah E. Empey to its B
AEON Biopharma, Inc. Files Amended 10-K for Fiscal Year Ended December 31, 2023 — 10-K/A · May 14, 2024 Risk: medium
AEON Biopharma, Inc. (AEON) filed a Amended Annual Report (10-K/A) with the SEC on May 14, 2024. AEON Biopharma, Inc. filed an amended 10-K for the fiscal year
AEON Biopharma Files 8-K with Financials and Updates — 8-K · May 3, 2024 Risk: low
AEON Biopharma, Inc. filed an 8-K on May 3, 2024, reporting on various events. The filing includes financial statements and exhibits, and is categorized under R
AEON Biopharma Withdraws Prior Financial Statements — 8-K · May 3, 2024 Risk: high
AEON Biopharma, Inc. announced on May 1, 2024, that it will not rely on previously issued financial statements. This decision impacts financial reporting and ma
AEON Biopharma, Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 29, 2024 Risk: low
AEON Biopharma, Inc. (AEON) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. AEON Biopharma, Inc. will hold its 2024 Annual Meeting of Stockhol
AEON Biopharma Closes $1.5M Private Placement — 8-K · Apr 17, 2024 Risk: medium
AEON Biopharma, Inc. announced on April 12, 2024, the closing of a private placement of its common stock and warrants, raising approximately $1.5 million. The c
AEON Biopharma Files 8-K for Financials — 8-K · Apr 15, 2024 Risk: low
AEON Biopharma, Inc. filed an 8-K on April 15, 2024, reporting on financial statements and exhibits. The company, formerly known as Priveterra Acquisition Corp.
AEON Biopharma, Inc. Files S-1/A Amendment — S-1/A · Apr 2, 2024 Risk: low
AEON Biopharma, Inc. (AEON) filed a Amended IPO Registration (S-1/A) with the SEC on April 2, 2024. Filing is an S-1/A amendment for AEON Biopharma, Inc. The co
AEON Biopharma, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 29, 2024 Risk: low
AEON Biopharma, Inc. (AEON) filed a Annual Report (10-K) with the SEC on March 29, 2024. AEON Biopharma, Inc. filed its annual report for the fiscal year ended
AEON Biopharma Enters Material Definitive Agreement — 8-K · Mar 28, 2024 Risk: medium
AEON Biopharma, Inc. entered into a material definitive agreement on March 24, 2024. This filing also indicates the creation of a direct financial obligation or
AEON Biopharma Files 8-K: Agreements, Sales, and Financials — 8-K · Mar 19, 2024 Risk: medium
On March 18, 2024, AEON Biopharma, Inc. entered into a material definitive agreement and also terminated a material definitive agreement. The company also discl
AEON Biopharma Flags Non-Reliance on Past Financials — 8-K · Feb 16, 2024 Risk: high
AEON Biopharma, Inc. filed an 8-K on February 16, 2024, reporting that its previously issued financial statements, specifically those related to common stock an
SC 13G Filing — SC 13G · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 14, 2024

Risk Profile

Risk Assessment: Of AEON's 46 recent filings, 7 were flagged as high-risk, 16 as medium-risk, and 23 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Aeon Biopharma, INC.'s most recent 10-Q filing (Nov 14, 2025):

Revenue: N/A
Net Income: -$2.085M
EPS: N/A
Debt-to-Equity: N/A
Cash Position: $5.927M
Operating Margin: N/A
Total Assets: $8.734M
Total Debt: $28.606M

Key Executives

Robert Bancroft
Alex Wilson
Dr. Robert L. Ferris
Ms. Sarah E. Empey

Industry Context

AEON Biopharma operates in the competitive biopharmaceutical sector, focusing on developing biosimilars. The market for biosimilars, particularly for high-value biologics like BOTOX, is growing due to patent expirations and the potential for cost savings. However, the development and commercialization of biosimilars require significant capital investment, rigorous regulatory approval processes, and strategic partnerships to navigate market entry and competition from established players.

Top Tags

financials (10) · corporate-governance (5) · Biopharma (4) · regulatory-filing (4) · financial-reporting (4) · AEON Biopharma (4) · material-agreement (3) · equity-sale (3) · disclosure (3) · SEC Filing (3)

Key Numbers

Shares of Class A Common Stock: 4,616,924 — Proposed issuance in PIPE Financing
Warrants to purchase Common Stock: 6,581,829 — Proposed issuance in PIPE Financing
New Senior Secured Convertible Note: $1,500,000 — Principal amount in Exchange Proposal with Daewoong
Warrant to purchase Common Stock: 8,000,000 — Shares purchasable via warrant in Exchange Proposal with Daewoong
Special Meeting Date: January 21, 2026 — Date for stockholder vote on proposals
Record Date: December 15, 2025 — Eligibility for voting at Special Meeting
Shares of Common Stock Outstanding: 12,105,902 — As of the Record Date, entitled to vote
Quorum Requirement: 33.34% — Percentage of voting power required for transaction of business
Report Date: 20251215 — Date of the earliest event reported in the 8-K filing.
Net Loss: $2.085M — for the nine months ended September 30, 2025, an improvement from $39.923M net income in 2024
Cash and Cash Equivalents: $5.927M — as of September 30, 2025, up from $13K at December 31, 2024
Accumulated Deficit: $433.7M — as of September 30, 2025, indicating significant historical losses
Proceeds from Public Offering: $18.346M — net cash provided by financing activities in 2025
Selling, General and Administrative Expenses: $8.316M — for the nine months ended September 30, 2025, down from $11.014M in 2024
Research and Development Expenses: $2.485M — for the nine months ended September 30, 2025, down from $11.144M in 2024

Related Companies

ABBV

Frequently Asked Questions

What are the latest SEC filings for Aeon Biopharma, INC. (AEON)?

Aeon Biopharma, INC. has 49 recent SEC filings from Feb 2024 to Dec 2025, including 29 8-K, 5 10-Q, 4 DEF 14A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of AEON filings?

Across 49 filings, the sentiment breakdown is: 6 bearish, 41 neutral, 2 mixed. The dominant sentiment is neutral.

Where can I find Aeon Biopharma, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Aeon Biopharma, INC. (AEON) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Aeon Biopharma, INC.?

Key financial highlights from Aeon Biopharma, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for AEON?

The investment thesis for AEON includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Aeon Biopharma, INC.?

Key executives identified across Aeon Biopharma, INC.'s filings include Robert Bancroft, Alex Wilson, Dr. Robert L. Ferris, Ms. Sarah E. Empey.

What are the main risk factors for Aeon Biopharma, INC. stock?

Of AEON's 46 assessed filings, 7 were flagged high-risk, 16 medium-risk, and 23 low-risk.

What are recent predictions and forward guidance from Aeon Biopharma, INC.?

Forward guidance and predictions for Aeon Biopharma, INC. are extracted from SEC filings as they are enriched.